| abstract |
The present disclosure relates to methods for treating or preventing heart failure using glucagon receptor blockers. In various embodiments, the disclosure provides heart failure (eg, post-myocardial infarction heart failure) using an antagonistic antigen binding protein, such as a fully human antibody, that specifically binds to and antagonizes the function of the human glucagon receptor, It relates to a method for treating or preventing diabetic cardiomyopathic heart failure) and lateral ventricular (LV) remodeling. [Selection] FIG. |